Valneva (NASDAQ:VALN) Shares Gap Down – Here’s What Happened

Valneva SE Sponsored ADR (NASDAQ:VALN)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $6.25, but opened at $5.92. Valneva shares last traded at $5.9410, with a volume of 4,551 shares.

Valneva Trading Down 2.6%

The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85. The company’s fifty day moving average is $9.34 and its 200-day moving average is $9.42. The stock has a market cap of $524.41 million, a PE ratio of -3.85 and a beta of 1.97.

Valneva (NASDAQ:VALN) last issued its earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share (EPS) for the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%.The business had revenue of $55.92 million for the quarter. On average, analysts predict that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the fourth quarter valued at $44,000. Marex Group plc purchased a new position in Valneva in the second quarter valued at $64,000. XTX Topco Ltd purchased a new position in Valneva in the fourth quarter valued at $94,000. VSM Wealth Advisory LLC increased its holdings in Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Valneva in the third quarter valued at $124,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.